SLAMF7 and Miyoshi myopathy: A single-arm phase 1/2a clinical trial (NCT04662099) was designed to evaluate the feasibility, safety, and efficacy of bispecific CS1/BCMA-targeted CAR-T cells in patients with r/r MM.